Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science’s Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

The Japanese HIV market also differs from that of the US and the 5EU in that the uptake of STRs has been less pronounced. For example, Atripla, which has become a leading HIV drug across the 6MM, is not currently licensed in Japan. Gilead’s Stribild, an INI-based STR that was approved by the FDA in August 2012, became the first STR to be licensed in Japan, in early 2013 (Japan Tobacco, press release, March 25, 2013).

Browse Full Research Report With TOC:  http://www.radiantinsights.com/research/human-immunodeficiency-virus-hiv-japan-drug-forecast-and-market-analysis-to-2023

Scope:
–    Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
–    Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
–    Sales forecast for the top drugs in the Japan from 2013-2023.
–    Analysis of the impact of key events as well the drivers and restraints affecting the Japan Human Immunodeficiency Virus (HIV) market.

Reasons to Buy:
–    Understand and capitalize by identifying products that are most likely to ensure a robust return
–    Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV).
–    Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
–    Make more informed business decisions from insightful and in-depth analysis of drug performance
–    Obtain sales forecast for drugs from 2013-2023 in the Japan.

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s